Breaking News

Pathalys Pharma Closes $105M Series B Financing Round

The funds pave the path to NDA submission and pre-commercialization efforts for upacicalcet.

Author Image

By: Charlie Sternberg

Associate Editor

Pathalys Pharma Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, plus support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.    “Since our i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters